Principia Biopharma

Company snapshot

We are a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology. Our proprietary Tailored Covalency® platform enables us to design and develop reversible and irreversible covalent small molecule inhibitors with potencies and selectivities that we believe will rival those of injectable biol

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Principia Biopharma. Not investment advice.

• What is Principia Biopharma?

  Principia Biopharma, a is a biotech organization headquartered in WILMINGTON, US. Primary therapeutic focus areas include Immune Thrombocytopenia. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTr

• Is Principia Biopharma publicly traded?

  Principia Biopharma appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Principia Biopharma develop or market?

  We link 1 drug profile(s) where Principia Biopharma is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/sanofi-pasteur-europe#company-drugs.

• What are the latest developments for Principia Biopharma?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Principia Biopharma focus on?

  Principia Biopharma focuses on Immune Thrombocytopenia based on our analysis of their pipeline programs and drug development activities.